2-Pyrimidineethanesulfonamide, N-[4-(2,6-dimethoxyphenyl)-5-(5-methyl-3-pyridinyl)-4H-1,2,4-triazol-3-yl]-α,5-dimethyl-β-(1-methylethoxy)-, (αS,βS)- manufacturers
- AM-8123
-
- $293.00
-
2026-07-27
- CAS:2049973-02-4
- Purity: 99.76%
- Supply Ability: 10g
|
| | 2-Pyrimidineethanesulfonamide, N-[4-(2,6-dimethoxyphenyl)-5-(5-methyl-3-pyridinyl)-4H-1,2,4-triazol-3-yl]-α,5-dimethyl-β-(1-methylethoxy)-, (αS,βS)- Basic information |
| Product Name: | 2-Pyrimidineethanesulfonamide, N-[4-(2,6-dimethoxyphenyl)-5-(5-methyl-3-pyridinyl)-4H-1,2,4-triazol-3-yl]-α,5-dimethyl-β-(1-methylethoxy)-, (αS,βS)- | | Synonyms: | 2-Pyrimidineethanesulfonamide, N-[4-(2,6-dimethoxyphenyl)-5-(5-methyl-3-pyridinyl)-4H-1,2,4-triazol-3-yl]-α,5-dimethyl-β-(1-methylethoxy)-, (αS,βS)-;AM-8123 | | CAS: | 2049973-02-4 | | MF: | C27H33N7O5S | | MW: | 567.67 | | EINECS: | | | Product Categories: | | | Mol File: | 2049973-02-4.mol | ![2-Pyrimidineethanesulfonamide, N-[4-(2,6-dimethoxyphenyl)-5-(5-methyl-3-pyridinyl)-4H-1,2,4-triazol-3-yl]-α,5-dimethyl-β-(1-methylethoxy)-, (αS,βS)- Structure](CAS/20211123/GIF/2049973-02-4.gif) |
| | 2-Pyrimidineethanesulfonamide, N-[4-(2,6-dimethoxyphenyl)-5-(5-methyl-3-pyridinyl)-4H-1,2,4-triazol-3-yl]-α,5-dimethyl-β-(1-methylethoxy)-, (αS,βS)- Chemical Properties |
| Boiling point | 754.1±70.0 °C(Predicted) | | density | 1.33±0.1 g/cm3(Predicted) | | pka | 4.07±0.10(Predicted) |
| | 2-Pyrimidineethanesulfonamide, N-[4-(2,6-dimethoxyphenyl)-5-(5-methyl-3-pyridinyl)-4H-1,2,4-triazol-3-yl]-α,5-dimethyl-β-(1-methylethoxy)-, (αS,βS)- Usage And Synthesis |
| Uses | AM-8123 is an orally active and potent APJ agonist. AM-8123 inhibits Forskolin-stimulated cAMP production and promotes Gα protein activation. AM-8123 can be used for the research of cardiovascular disease[1]. | | in vivo | AM-8123 (100 mg/kg; p.o.) results in sustained improvement in systolic function and decreases both EDV and ESV as measured by echocardiography but not by the invasive pressure-volume conductance catheter at study termination[1].
AM-8123 (0.035, 0.09, 0.9, and 9 mg/kg; i.v.) improves cardiovascular function[1].
AM-8123 exhibits appreciably greater oral bioavailability in rats and dogs relative to pyr-apelin-13. AM-8123 infusion results in an increase in EF, SV, and dP/dt max at submicromolar unbound plasma concentrations with minimal change in HR, indicating that acute infusion of AM-8123 is associated with an improvement in several markers of cardiac function. AM-8123 is a more potent mediator of both ERK and AKT phosphorylation relative to pyr-apelin-13[1]. | Animal Model: | Lewis rats (2~3 months old)[1] | | Dosage: | 100 mg/kg | | Administration: | P.o. | | Result: | Resulted in sustained improvement in systolic function.
Decreased both EDV and ESV as measured by echocardiography but not by the invasive pressure-volume conductance catheter at study termination.
|
| Animal Model: | Rats[1] | | Dosage: | 0.035, 0.09, 0.9, and 9 mg/kg | | Administration: | I.v. | | Result: | Improved cardiovascular function.
|
| | References | [1] Ason B, et al. Cardiovascular response to small-molecule APJ activation. JCI Insight. 2020;5(8):e132898. Published 2020 Apr 23. doi:10.1172/jci.insight.132898 |
| | 2-Pyrimidineethanesulfonamide, N-[4-(2,6-dimethoxyphenyl)-5-(5-methyl-3-pyridinyl)-4H-1,2,4-triazol-3-yl]-α,5-dimethyl-β-(1-methylethoxy)-, (αS,βS)- Preparation Products And Raw materials |
|